TB-500 + BPC-157 Stack
Anonymous reports on running TB-500 and BPC-157 together. Injury recovery timelines, stacking protocols, and what users noticed that clinical literature doesn't cover.
7 anonymous reports
Community Q&A
- What does the TB-500 and BPC-157 stack do?
- Community accounts describe the combination as complementary: BPC-157 is characterised as a localised healing signal (gut lining, tendons, ligaments), while TB-500 is described as systemic — reducing inflammation broadly and promoting tissue remodelling. Accounts using both consistently describe faster recovery than either alone. The stack is most common in injury-recovery contexts but also appears in prophylactic accounts during heavy training blocks.
- How do you dose TB-500 and BPC-157 together?
- Community conventions for the combined stack: BPC-157 at 250–500mcg daily or twice daily near the injury site, TB-500 at 2–5mg twice weekly systemically. The two are typically injected separately — accounts combining them in the same syringe exist but are less common. Loading phase duration in confessions is usually 4–6 weeks for acute injuries, 8–12 weeks for chronic issues. Maintenance dosing (once weekly each) appears in accounts from users who cycle the stack preventatively.
- What injuries does the TB-500 BPC-157 stack help most?
- Community accounts cluster around specific injury types: tendon injuries (Achilles, rotator cuff, patellar) are the most frequently described success stories; ligament sprains and partial tears appear with strong positive outcomes; muscle tears and strains appear with faster recovery timelines than tendon accounts. Gut injury accounts (IBD flares, leaky gut, NSAID damage) appear predominantly in BPC-157-only protocols rather than the full stack — the gut healing use case rarely requires TB-500's systemic mechanism. Post-surgical orthopedic recovery is where the full stack appears most consistently in medical-adjacent accounts.
- Can you take TB-500 and BPC-157 orally?
- Community accounts split by compound. BPC-157: oral accounts are common and describe meaningful effects for gut-specific applications — IBD, gastric issues, gut lining repair — with the argument that gut absorption is sufficient for local gut healing. TB-500: oral accounts are rare and sceptical — most community accounts treat subcutaneous injection as necessary for TB-500's systemic mechanism. Accounts that tried oral TB-500 for injury recovery describe minimal effect compared to injection. The practical split in community protocols: oral BPC-157 for gut goals, subcutaneous BPC-157 for injury goals, subcutaneous TB-500 for all TB-500 applications.